02.09.15
Ligand
4Q Revenues: $23.0 million (+56%)
4Q Earnings: $7.1 million (+278%)
FY Revenues: $64.5 million (+32%)
FY Earnings: $12.0 million (+5%)
Comments: Royalty revenues increased 32% in the quarter to $9.4 million primarily due to higher royalties from Promaca and Kyprolis. Material sales increased to $13.0 million from $6.8 million in 4Q13 due to higher demand for Captisol for both clinical and commercial uses.
4Q Revenues: $23.0 million (+56%)
4Q Earnings: $7.1 million (+278%)
FY Revenues: $64.5 million (+32%)
FY Earnings: $12.0 million (+5%)
Comments: Royalty revenues increased 32% in the quarter to $9.4 million primarily due to higher royalties from Promaca and Kyprolis. Material sales increased to $13.0 million from $6.8 million in 4Q13 due to higher demand for Captisol for both clinical and commercial uses.